Phaseline

Targets › MYL2

MYL2 (Myosin regulatory light chain 2, ventricular/cardiac muscle isoform): drug programs, companies and trials

3 programs from 3 companies in 6 trials: 3 Phase 3, 2 Phase 4, 1 Phase 2; Cardiovascular; next expected readout Jun 2027.

Contractile protein that plays a role in heart development and function. Following phosphorylation, plays a role in cross-bridge cycling kinetics and cardiac muscle contraction by increasing myosin lever arm stiffness and promoting myosin head diffusion; as a consequence of the increase in maximum contraction force and calcium sensitivity of contraction force. (UniProt, P10916)

Open in Phaseline: the race on MYL2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbMavacamten (BMS-986427)
Cardiac myosin inhibitor
MYH7, MYH6, MYH7B, MYL3, MYL2Phase 4Cardiomyopathy, Hypertrophic; Symptomatic Obstructive Hypertrophic CardiomyopathyJun 2027
CytokineticsOmecamtiv Mecarbil
Cardiac myosin activator
MYH7, MYH6, MYH7B, MYL3, MYL2Phase 3Heart FailureSep 2027
Kardigandanicamtiv
Cardiac myosin activator
MYH7, MYH6, MYH7B, MYL3, MYL2Phase 3Symptomatic Genetic Dilated Cardiomyopathy (DCM); Symptomatic Genetic Dilated CardiomyopathySep 2027

Conditions

Cardiomyopathy, Hypertrophic (2) Symptomatic Obstructive Hypertrophic Cardiomyopathy (1) Symptomatic Genetic Dilated Cardiomyopathy (DCM) (1) Symptomatic Genetic Dilated Cardiomyopathy (1) Heart Failure (1)

Modalities

small molecule (3)

Companies

Bristol-Myers Squibb (1) Kardigan (1) Cytokinetics (1)

Related targets

MYH7 (3) MYH6 (3) MYH7B (3) MYL3 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.